Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Can016

Preclinical

CCanwell Biotech Limited

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Patients With Advanced Solid TumorsNot yet recruiting

Patients With Advanced Solid TumorsPreclinical

Not yet recruiting

Timeline

Expected Milestones

Q4 2029

PreclinicalRecruiting

Patients With Advanced Solid Tumors

NCT07664150

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

A Phase I/II, Open-Label, Non-Randomized, Multi-Centre First-in-Human Study of CAN016 in Patients With Advanced Solid Tumors

Recruiting·CCanwell Biotech Limited·Preclinical·NCT07664150·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Can016. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Can016. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Canwell Biotech Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: CCanwell Biotech Limited

Related News